HealthExec January 8, 2024
Boston Scientific Corp. is purchasing Axonics in a move the buyer says will allow it to pursue an “underpenetrated” segment of the urology market—one that’s expected to grow from $800 million in 2022 to $1.6 billion over the next five years.
The segment is sacral neuromodulation (SNM) therapy, an Axonics specialty. The technology restores brain-bladder communications by delivering mild electrical pulses to the sacral nerve. Used for minimally invasive therapy, SNM has been shown effective for not only overactive bladder but also fecal incontinence.
Boston Sci points out the Axonics technology showed meaningful improvement in patients’ quality of life for up to two years in clinical trials. The researchers also reported no serious device-related adverse events.
Boston Sci says the...
Today's Sponsors
Today's Sponsor